Ann: MLA Subsidiary to help Develop Canine Cancer Treatment, page-3

Human health sounds very interesting nice how that was thrown in at the end.

This stock is still very under the radar but with some strong news this will fly.

Its good to see that when a medivet report goes out that it is listed as a subsidiary of MLA quite reassuring that transition has been completed.

I still think we have a long way to go but it seems medivet is gaining respect in the US and maybe other universities may want to partner with us.

If this ground breaking drug is successful this Stock could easily be over $1 one day like BLT. I had BLT on my watchlist at 5c then boom over $3 in a month. That brought a tear to my eye but the same could happen to MLA in the future.